SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., (NASDAQ:DXCM), the leader in continuous glucose monitoring (CGM), announced today that it has received U.S. Food and Drug Administration (FDA) approval for ...

テルモ株式会社（本社:東京都渋谷区、社長:佐藤 慎次郎）は、本日2月28日、持続血糖測定器「Dexcom G4 PLATINUMシステム」（デクスコム G4 プラチナムシステム）を、全国の医療機関に向けて発売しました。本製品は、持続血糖測定器で世界トップシェアの米国デ ...

DexCom’s shares shot up as much as 8% in the trading session following the announcement. The stock has been up 2.6% since the news release. Currently, the DexCom G4 PLATINUM (Pediatric) is the only ...

, a leader in continuous glucose monitoring, announced today that the U.S. Food and Drug Administration has approved its eagerly anticipated new continuous glucose monitoring system, the Dexcom G4™ ...

Dexcom has announced it has received FDA approval of a new continuous glucose monitoring system, according to a news release. The Dexcom G4 PLATINUM system consists of three parts: a sensor, ...

The Julphar revolutionary real-time continuous glucose monitoring device (CGM), Dexcom G4 Platinum is now available in UAE, KSA, Kuwait and Oman and will soon be available in Qatar, Bahrain and ...

Dexcom has received approval from the FDA for a new version of its smartphone connected Dexcom Share platform that will eliminate the docking cradle and allow a patient's continuous glucose monitor ...